Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations

Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation,...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Isaac E. Kim [verfasserIn] Daniel D. Kim [verfasserIn] Sinae Kim [verfasserIn] Shuangge Ma [verfasserIn] Thomas L. Jang [verfasserIn] Eric A. Singer [verfasserIn] Saum Ghodoussipour [verfasserIn] Isaac Yi Kim [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Prostate cancer Insurance Survival disparity SEER

Übergeordnetes Werk:	In: BMC Urology - BMC, 2003, 22(2022), 1, Seite 11
Übergeordnetes Werk:	volume:22 ; year:2022 ; number:1 ; pages:11

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/s12894-022-01045-0

Katalog-ID:	DOAJ039107787

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ039107787
003	DE-627
005	20230308025553.0
007	cr uuu---uuuuu
008	230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s12894-022-01045-0 \|2 doi
035			\|a (DE-627)DOAJ039107787
035			\|a (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC870-923
100	0		\|a Isaac E. Kim \|e verfasserin \|4 aut
245	1	0	\|a Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.
650		4	\|a Prostate cancer
650		4	\|a Insurance
650		4	\|a Survival disparity
650		4	\|a SEER
653		0	\|a Diseases of the genitourinary system. Urology
700	0		\|a Daniel D. Kim \|e verfasserin \|4 aut
700	0		\|a Sinae Kim \|e verfasserin \|4 aut
700	0		\|a Shuangge Ma \|e verfasserin \|4 aut
700	0		\|a Thomas L. Jang \|e verfasserin \|4 aut
700	0		\|a Eric A. Singer \|e verfasserin \|4 aut
700	0		\|a Saum Ghodoussipour \|e verfasserin \|4 aut
700	0		\|a Isaac Yi Kim \|e verfasserin \|4 aut
773	0	8	\|i In \|t BMC Urology \|d BMC, 2003 \|g 22(2022), 1, Seite 11 \|w (DE-627)335488811 \|w (DE-600)2059857-9 \|x 14712490 \|7 nnns
773	1	8	\|g volume:22 \|g year:2022 \|g number:1 \|g pages:11
856	4	0	\|u https://doi.org/10.1186/s12894-022-01045-0 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 \|z kostenfrei
856	4	0	\|u https://doi.org/10.1186/s12894-022-01045-0 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1471-2490 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 22 \|j 2022 \|e 1 \|h 11

Indexfelder

author_variant	i e k iek d d k ddk s k sk s m sm t l j tlj e a s eas s g sg i y k iyk
matchkey_str	article:14712490:2022----::hneipottcnesriaaognueptetirltotupt
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11
spelling	10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11
allfields_unstemmed	10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11
allfieldsGer	10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11
allfieldsSound	10.1186/s12894-022-01045-0 doi (DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466 DE-627 ger DE-627 rakwb eng RC870-923 Isaac E. Kim verfasserin aut Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients. Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology Daniel D. Kim verfasserin aut Sinae Kim verfasserin aut Shuangge Ma verfasserin aut Thomas L. Jang verfasserin aut Eric A. Singer verfasserin aut Saum Ghodoussipour verfasserin aut Isaac Yi Kim verfasserin aut In BMC Urology BMC, 2003 22(2022), 1, Seite 11 (DE-627)335488811 (DE-600)2059857-9 14712490 nnns volume:22 year:2022 number:1 pages:11 https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 kostenfrei https://doi.org/10.1186/s12894-022-01045-0 kostenfrei https://doaj.org/toc/1471-2490 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 22 2022 1 11
language	English
source	In BMC Urology 22(2022), 1, Seite 11 volume:22 year:2022 number:1 pages:11
sourceStr	In BMC Urology 22(2022), 1, Seite 11 volume:22 year:2022 number:1 pages:11
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Prostate cancer Insurance Survival disparity SEER Diseases of the genitourinary system. Urology
isfreeaccess_bool	true
container_title	BMC Urology
authorswithroles_txt_mv	Isaac E. Kim @@aut@@ Daniel D. Kim @@aut@@ Sinae Kim @@aut@@ Shuangge Ma @@aut@@ Thomas L. Jang @@aut@@ Eric A. Singer @@aut@@ Saum Ghodoussipour @@aut@@ Isaac Yi Kim @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	335488811
id	DOAJ039107787
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039107787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308025553.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12894-022-01045-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039107787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56b5fe2d999a41a39991e88766b90466</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Isaac E. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival disparity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SEER</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel D. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sinae Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuangge Ma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas L. Jang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric A. Singer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saum Ghodoussipour</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isaac Yi Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Urology</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">22(2022), 1, Seite 11</subfield><subfield code="w">(DE-627)335488811</subfield><subfield code="w">(DE-600)2059857-9</subfield><subfield code="x">14712490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56b5fe2d999a41a39991e88766b90466</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">11</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Isaac E. Kim
spellingShingle	Isaac E. Kim misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
authorStr	Isaac E. Kim
ppnlink_with_tag_str_mv	@@773@@(DE-627)335488811
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC870-923
illustrated	Not Illustrated
issn	14712490
topic_title	RC870-923 Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations Prostate cancer Insurance Survival disparity SEER
topic	misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology
topic_unstemmed	misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology
topic_browse	misc RC870-923 misc Prostate cancer misc Insurance misc Survival disparity misc SEER misc Diseases of the genitourinary system. Urology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	BMC Urology
hierarchy_parent_id	335488811
hierarchy_top_title	BMC Urology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)335488811 (DE-600)2059857-9
title	Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
ctrlnum	(DE-627)DOAJ039107787 (DE-599)DOAJ56b5fe2d999a41a39991e88766b90466
title_full	Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
author_sort	Isaac E. Kim
journal	BMC Urology
journalStr	BMC Urology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	11
author_browse	Isaac E. Kim Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim
container_volume	22
class	RC870-923
format_se	Elektronische Aufsätze
author-letter	Isaac E. Kim
doi_str_mv	10.1186/s12894-022-01045-0
author2-role	verfasserin
title_sort	changes in prostate cancer survival among insured patients in relation to uspstf screening recommendations
callnumber	RC870-923
title_auth	Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
abstract	Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.
abstractGer	Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.
abstract_unstemmed	Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
url	https://doi.org/10.1186/s12894-022-01045-0 https://doaj.org/article/56b5fe2d999a41a39991e88766b90466 https://doaj.org/toc/1471-2490
remote_bool	true
author2	Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim
author2Str	Daniel D. Kim Sinae Kim Shuangge Ma Thomas L. Jang Eric A. Singer Saum Ghodoussipour Isaac Yi Kim
ppnlink	335488811
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s12894-022-01045-0
callnumber-a	RC870-923
up_date	2024-07-03T21:38:49.260Z
_version_	1803595524878630912
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039107787</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308025553.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12894-022-01045-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039107787</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ56b5fe2d999a41a39991e88766b90466</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Isaac E. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background To investigate the effects of the U.S. Preventive Services Task Force’s (USPSTF) 2012 recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer on survival disparities based on insurance status. Prior to the USPSTF’s 2012 screening recommendation, previous studies found that insured patients with prostate cancer had better outcomes than uninsured patients. Methods Using the SEER 18 database, we examined prostate cancer-specific survival (PCSS) based on diagnostic time period and insurance status. Patients were designated as belonging to the pre-USPSTF era if diagnosed in 2010–2012 or post-USPSTF era if diagnosed in 2014–2016. PCSS was measured with the Kaplan–Meier method, while disparities were measured with the Cox proportional hazards model. Results During the pre-USPSTF era, uninsured patients experienced worse PCSS compared to insured patients (adjusted HR 1.256, 95% CI 1.037–1.520, p = 0.020). This survival disparity was no longer observed during the post-USPSTF era as a result of decreased PCSS among insured patients combined with unchanged PCSS among uninsured patients (adjusted HR 0.946, 95% CI 0.642–1.394, p = 0.780). Conclusions Although the underlying reasons are not clear, the USPSTF’s 2012 PSA screening recommendation may have hindered insured patients from being regularly screened for prostate cancer and selectively led to worse outcomes for insured patients without affecting the survival of uninsured patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival disparity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SEER</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel D. Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sinae Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shuangge Ma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas L. Jang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric A. Singer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Saum Ghodoussipour</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Isaac Yi Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">BMC Urology</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">22(2022), 1, Seite 11</subfield><subfield code="w">(DE-627)335488811</subfield><subfield code="w">(DE-600)2059857-9</subfield><subfield code="x">14712490</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/56b5fe2d999a41a39991e88766b90466</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s12894-022-01045-0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1471-2490</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">11</subfield></datafield></record></collection>
score	7.4014053

Nicht das Richtige dabei?

Schreiben Sie uns!

Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?